Saving lives with an innovative coating for medical devices

  • Invest
  • Becoming Investor Ready
  • NOM Startup Program
  • Life Sciences & Health
Jurr Van Ramshorst

More than 70% of all hospital infections are caused by medical devices, such as catheters, infusion lines and implants. Groningen-based biotech startup Bioprex Medical has developed an innovative antibacterial coating to tackle this problem at the source.

The initial preclinical results are promising, and thanks to a new round of funding from Pharma Connect Capital and the NOM, the startup can continue developing its patented coating. Over the coming year, Bioprex will focus on the preclinical evaluation of the coating and on expanding partnerships with manufacturers of medical devices and implants.

According to the European Centre for Disease Prevention and Control, more than 4 million patients in Europe contract bacterial infections every year, often caused by medical devices and implants. "In Europe alone, about 90,000 people die each year from such infections. Treating them costs the health care system 7 billion euros annually," said Van Ramshorst. "It's a big problem that will only increase in the future. With our coating, we are tackling the problem at the source."

Prevention is better than cure

The need is high because treating bacterial infections is becoming increasingly difficult. This is because various bacteria are increasingly resistant to antibiotics, such as MRSA bacteria in hospitals. "Bacteria form a biofilm when they attach themselves to a surface," Van Ramshorst explains. "This is a protective layer that shields them from our immune system. Even antibiotics have difficulty penetrating this biofilm."

So as the age-old adage goes, prevention is better than cure. And that is exactly what Bioprex is doing. "Our coating uses quaternary ammonium compounds that kill bacteria when they try to adhere to the surface," Van Ramshorst said. "This coating can be used for various medical devices and implants, such as orthopedic pins and screws used to fix bone fractures, as well as catheters and permanent implants.

Spin-off

Bioprex Medicalwas founded two years ago as a spin-off from the Zernike Institute for Advanced Materials at the University of Groningen, but the idea for the coating has been around for more than 20 years. “Our CTO, Ton Loontjens, was already working on this idea at DSM back then, but the technology was still in its infancy,” says Van Ramshorst. “About ten years ago, Ton met co-founder Pieter André de la Porte, director of Zorg Innovaties Nederland, who was very interested in the commercial applications of the coating. In addition to his job at DSM, Ton was appointed as a professor at the University of Groningen (RUG), where he further developed the concept together with students and Ph.D. candidates, with the goal of eventually bringing the coating to market through a spin-off.”

Last year, Bioprex completed the first in vivo evaluations. "This allowed us to demonstrate the safety and effectiveness of the coating in living cells," says Van Ramshorst. "That yielded promising results. This year we are focusing on further preclinical evaluations, looking at long-term safety and efficacy, among other things."

Funding

Bioprex secured funding from the NOM, among others. “The societal value of this coating is enormous,” says Tristan Dikkers, investment manager at the NOM. “The NOM, together with Triade and RUG Ventures, was already involved in the first round of funding, which enabled Bioprex to develop a proof-of-concept. The initial preclinical results were promising, so we saw enough potential to participate in this round of funding as well. Moreover, it was great to see how Jurr has developed as an entrepreneur in such a short time.”

Pharma Connect Capital, an investment fund based in the northern Netherlands, also participated in the second round of funding. “With this antibacterial coating, Bioprex has a promising concept, so we’re happy to help the company take the next step,” says Jan Hendriks, fund manager at Pharma Connect Capital. “I also see a strong team behind this concept, which gives us a lot of confidence.”

Lessons learned

With this second round of funding, Bioprex can take important steps forward, but for a biotech startup, progress sometimes moves more slowly than desired. “Innovation in the life sciences requires patience, and we’ve experienced that firsthand,” says Van Ramshorst. “As an entrepreneur, you want to move forward quickly, but in the medical sector, you have to back everything up with solid evidence. It’s difficult for an early-stage startup with a new technology to raise funding, especially in Europe. That’s why we’re grateful to have the support of organizations like NOM, Triade, RUG Ventures, and Pharma Connect Capital at this early stage.”

Bioprex also participated in NOM’s Investor Readiness Program. “That was very valuable to us,” says Van Ramshorst. “We’re working toward a larger investment round, and this program gave us a good overview of what’s needed for that. We now have a much better understanding of how investors view our proposition.”

Collaborations with manufacturers

In addition to further testing and working toward another round of investment, Bioprex is focusing this year on expanding collaborations with medical device manufacturers. "Medical device manufacturers are often looking for plug-and-play solutions that are easy to integrate into their production process. This is why we are developing our coating as a platform technology that is widely applicable to different types of medical devices and implants." Currently, Bioprex's focus is on applying the coating to orthopedic pins and screws used to fix bone fractures. Eventually, they will also develop the coating for other medical devices, such as catheters and permanent implants. "Our goal is to prevent as many infections as possible," he said.